Trial Profile

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case : MECHANISM-Elective

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis; Stent thrombosis
Focus Therapeutic Use
Acronyms MECHANISM-Elective

02 Nov 2017 Results of a subanalysis assessing Coronary Risk Factors Associated with OCT Macrophage Images and their Response after stent implantation (n=89) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
29 Aug 2017 Planned End Date changed from 1 Jan 2015 to 31 Dec 2018.
29 Aug 2017 Planned primary completion date changed from 1 Jan 2015 to 31 Dec 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com